Table 1.
Characteristics by age in untreated HIV-infected children.
| Overall | Age < 1 year | Age 1 - 2 years | Age 2 - 5 years | Age 5 - 10 years | Age 10 - 15 years | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BASELINE | N = 405 | N = 64 | N = 42 | N = 108 | N = 142 | N = 49 | ||||||
| Age, years, median (IQR) | 4.5 | (1.9; 7.5) | 0.3 | (0.01; 0.6) | 1.7 | (1.6; 1.8) | 3.4 | (2.6; 4.1) | 7 | (5.9; 8.5) | 12.1 | (11.2; 13.1) |
| Female, n (%) | 189 | (46.7) | 30 | (46.9) | 19 | (45.2) | 47 | (43.5) | 75 | (52.8) | 18 | (36.7) |
| Weight available, n (%) | 383 | (94.6) | 59 | (92.2) | 37 | (88.1) | 100 | (92.6) | 138 | (97.2) | 49 | (100.0) |
| Height available, n (%) | 369 | (91.1) | 59 | (92.2) | 36 | (85.7) | 95 | -88 | 131 | (92.3) | 48 | (97.9) |
| Weight for age z-score, median (IQR) | -2.09 | (-3.45; -0.95) | - 1.94 | (-3.01; -0.91) | -2.67 | (-4.10; -1.60) | -1.93 | (-3.36; -0.74) | -1.84 | (-3.22; -0.75) | -2.58 | (-4.05; -1.62) |
| Height for age z-score, median (IQR) | -1,59 | (-2;69; -0.76) | - | -1.34 | (-1.47; -0.93) | -1.79 | (-3.01; -0.74) | -1.32 | (-2.44; -0.72) | -1.88 | (-2.79; -1.06) | |
| Weight for height z-score, median (IQR) | -1,11 | (-2.63; -0.21) | - | -1.33 | (-1.32; -0.38) | -0.86 | (-2.37; 0.06) | -1.38 | (-3.57; -0.43) | -1.67 | (-1.85; -1.49) | |
| Failure to thrive, n (%) | 198 | (51.7) | 29 | (49.2) | 26 | (70.3) | 48 | -48 | 63 | (45.7) | 32 | (65.3) |
| CD4 count measurement available, n (%) | 308 | (76.1) | 36 | (56.3) | 36 | (85.7) | 92 | (85.2) | 106 | (74.6) | 38 | (94) |
| CD4 cell %, median (IQR) | 19 | (14; 25.5) | 18.3 | (14.1; 26) | 17.9 | (11.7; 23.3) | 20.7 | (14; 26.2) | - | - | ||
| CD4 count/μL, median (IQR) | 403 | (151; 665) | - | - | - | 507.5 | (234; 723) | 213.5 | (55; 413) | |||
| Immunodepressed* children*, n (%) | 112 | (27.7) | 10 | (15.6) | 10 | (15.6) | 26 | (24.1) | 39 | (27.5) | 27 | (55.1) |
| CDC stage C, n (%) | 50 | (12.3) | 7 | (10.9) | 6 | (14.3) | 12 | (11.1) | 14 | (9.9) | 11 | (2.1) |
| Baseline cotrimoxazole prophylaxis n (%) | 271 | (66.9) | 23 | (35.9) | 33 | (78.6) | 74 | (68.5) | 102 | (71.8) | 39 | (67.4) |
| Born to known HIV-infected mothers | 273 | (67.4) | 64 | (100) | 33 | (78.6) | 86 | (76.6) | 77 | (54.2) | 13 | (26.5) |
| Diagnosis by PCR before 18 months | 71 | (19.2) | 53 | (82.8) | 6 | (14.3) | 5 | (4.6) | 6 | (4.2) | 1 | (2.1) |
| Mother deceased at inclusion, n (%) | 97 | (30.9) | 1 | (1.6) | 1 | (2.4) | 15 | (13.9) | 52 | (36.6) | 28 | (57.1) |
| Breastfeeding history, n (%) | 191 | (47.2) | 40 | (62.5) | 19 | (45.2) | 43 | (39.9) | 67 | (47.2) | 22 | (44.9) |
| History of PMTCT intervention | 65 | (18.1) | 50 | (78.1) | 10 | (23.8) | 5 | (4.6) | - | - | ||
Children followed-up by the CePReF and the MTCT-Plus programme, Abidjan, Côte d'Ivoire (January-2004-December 2009). n = 405. * Immunodeficiency according to the 2006 criteria;